Drugs / H4:IC31
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02378207 | May 2015 → Oct 2016 | tuberculosis | Aeras | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H4:IC31 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02378207 ↗ |
| Known as | AERAS-404 | “This study will complement one ongoing study (NCT02075203) evaluating the prevention of M. Tuberculosis infection using H4:IC31 (also known as AERAS-404).” NCT02378207 ↗ |
| Modality | Vaccine | “Two doses of H4:IC31 and H56:IC31 vaccines were administered intramuscularly (IM) 56 days apart” PMID 32382714 ↗ Mar 2020 |
| Route | Intramuscular | “Two doses of H4:IC31 and H56:IC31 vaccines were administered intramuscularly (IM) 56 days apart” PMID 32382714 ↗ Mar 2020 |